Johnson & Johnson (NYSE:JNJ) Shares Purchased by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 137.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,568 shares of the company’s stock after buying an additional 25,203 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Johnson & Johnson were worth $7,061,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Black Diamond Financial LLC boosted its position in shares of Johnson & Johnson by 5.0% during the third quarter. Black Diamond Financial LLC now owns 2,885 shares of the company’s stock worth $467,000 after buying an additional 138 shares during the period. CIBC Asset Management Inc grew its position in Johnson & Johnson by 5.6% in the 3rd quarter. CIBC Asset Management Inc now owns 634,722 shares of the company’s stock valued at $102,851,000 after acquiring an additional 33,454 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co increased its stake in Johnson & Johnson by 0.3% during the third quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 129,872 shares of the company’s stock worth $21,047,000 after purchasing an additional 410 shares during the period. Intellectus Partners LLC boosted its stake in shares of Johnson & Johnson by 5.2% in the third quarter. Intellectus Partners LLC now owns 9,315 shares of the company’s stock valued at $1,510,000 after purchasing an additional 461 shares during the period. Finally, Balboa Wealth Partners increased its stake in Johnson & Johnson by 3.7% during the 3rd quarter. Balboa Wealth Partners now owns 7,549 shares of the company’s stock worth $1,223,000 after buying an additional 267 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.0 %

JNJ stock opened at $151.84 on Friday. The company has a market cap of $365.57 billion, a price-to-earnings ratio of 21.98, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53. The company has a fifty day moving average price of $161.82 and a 200 day moving average price of $155.99. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the company earned $2.66 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. Sell-side analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Citigroup boosted their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. TD Securities reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.94.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.